Drug Profile
Research programme: immunotherapies - Cartesian Therapeutics
Latest Information Update: 05 Dec 2023
Price :
$50
*
At a glance
- Originator Sanofi
- Developer Cartesian Therapeutics; Sanofi
- Class Vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Coeliac disease; Food hypersensitivity
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for preclinical development in Coeliac disease in USA (Parenteral)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Food-hypersensitivity in USA (Parenteral)
- 06 Feb 2017 Preclinical trials in Coeliac disease in USA (Parenteral) before February 2017